Day: March 6, 2026

TEN, Ltd. Reports Profits for the Twelve-Months and Fourth Quarter Ended December 31, 2025

Written by Customer Service on March 6, 2026. Posted in Earnings Releases And Operating Results.

200% Q-O-Q increase in net income to $58 million in Q4 2025 $800 million of gross revenues and $161 million of net income for 2025 ($4.45 per share) $416 million in adj. EBITDA in 2025 TEN benefitting from historical high tanker rates. Timely NB orders of LNG & VLCCs $4 billion in Minimum Contracted Revenue ATHENS, Greece, March 06, 2026 (GLOBE NEWSWIRE) — TEN, Ltd (TEN) (NYSE: TEN) (the “Company”) today reported results (unaudited) for the twelve months and fourth quarter ended December 31, 2025. TWELVE MONTHS 2025 SUMMARY RESULTSTEN’s fleet for the twelve months of 2025, generated close to $800 million in gross revenues, and approx. $252 million in operating income inclusive of $12.5 million in capital gains from the sale of four older vessels. Net income for the twelve months of 2025 was $161 million or $4.45 per share. Adjusted...

Catheter Precision’s LockeT Suture Retention Device to be Featured in Live Cases at ISLAA 2026

Written by Customer Service on March 6, 2026. Posted in Public Companies.

FORT MILL, S.C., March 06, 2026 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (NYSE American: VTAK), a pioneer in medical technology for the cardiac electrophysiology market, today announced that its LockeT suture retention device will be highlighted during live procedural cases at the International Symposium of Left Atrial Appendage 2026 conference. The event, co-hosted by the Academy for Continued Healthcare Learning (ACHL) and ISLAA Foundation, will take place from March 5-6, 2026, at the Biltmore Hotel in Los Angeles, California. The ISLAA meeting is a multi-specialty cardiovascular educational symposium on the frontier science of left atrial appendage (LAA). Over two days, course directors and leading physicians from The Kansas City Heart Rhythm Institute, Texas Cardiac Arrhythmia Institute, Los Robles Medical Center, Mayo...

Cohen & Company Reports Fourth Quarter & Full Year 2025 Financial Results

Written by Customer Service on March 6, 2026. Posted in Public Companies.

Board Declares Quarterly Dividend of $0.25 per Share and Special Dividend of $0.70 per Share Revenue of $102.7 Million in Fourth Quarter 2025 and $275.6 Million in Full Year 2025 Net Income Attributable to Cohen & Company Inc. of $8.1 Million, or $1.48 per Diluted Share, in Fourth Quarter 2025 and $14.4 Million, or $4.35 per Diluted Share, in Full Year 2025 Adjusted Pre-Tax Income of $18.3 Million, or $2.97 per Diluted Share, in Fourth Quarter 2025 and $41.4 Million, or $6.92 per Diluted Share, in Full Year 2025 PHILADELPHIA and NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) — Cohen & Company Inc. (NYSE American: COHN) today reported financial results for its fourth quarter and full year ended December 31, 2025. Summary Operating Results Three Months Ended Twelve...

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Written by Customer Service on March 6, 2026. Posted in Public Companies.

Extends Company Cash Runway into Mid-2028Financing Expected to Fund Completion of Phase 2 Ovarian Cancer TrialFinancing Supports Acceleration Toward Pivotal Trial and Commercialization Financing Structured as Non-Convertible Debt FinancingTARPON SPRINGS, Fla., March 6, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that it has closed a $20 million non-convertible debt financing with Streeterville Capital. The transaction is structured as a note purchase agreement pursuant to which the Company issued two non-convertible promissory notes: (i) a promissory note in the original principal amount of $10,930,000 and (ii) a secured promissory...

CORRECTION vol2: Eesti Energia Group Unaudited Results for 2025

Written by Customer Service on March 6, 2026. Posted in Public Companies.

Correction has been made to the consolidated interim income statement: comparative periods for 25H2 and 24H2 have been added. — Sales Revenues and Profitability In 2025, the Baltic energy sector experienced significant developments and challenges, both of which had a major impact on energy security and prices. The energy market, which was previously stable and predictable, has undergone rapid changes in recent years, with prices becoming increasingly volatile. In 2025 sales revenue totalled EUR 1,646.9 million, an 8% decrease year-on-year. EBITDA declined to EUR 317.2 million, an 20% decrease year-on-year. Reported net loss for the year was EUR 82.6 million (EUR –95.5 million year-on-year). The net loss for 2025 includes asset impairments in the amount of EUR 197.6 million, of which EUR 194.5 million are related to oil production...

VEON and JazzWorld Advance Pakistan’s Digital Financial Future with Acquisition of TPL Insurance

Written by Customer Service on March 6, 2026. Posted in Mergers And Acquisitions.

Acquisition to further financial inclusion through integrated digital financial services ecosystem Dubai, New York and Karachi – March 6, 2026 – VEON Ltd. (Nasdaq: VEON, “VEON”), a global digital operator, today announced that its subsidiary Jazz International Holding Limited (“JIH”) has entered into a definitive agreement to acquire a controlling stake in TPL Insurance Limited (“TPL Insurance”), a publicly listed insurance firm in Pakistan. The transaction, which marks a new milestone for VEON’s growing digital financial services portfolio in one of its most dynamic growth markets, is expected to close in mid-2026, subject to regulatory approvals. TPL Insurance, a digital-first insurance provider in Pakistan, offers auto, health, fire and property insurance products through its well-established distribution capabilities, and holds a general...

Virtuix Rings the Nasdaq Closing Bell Celebrating its Listing on the Nasdaq Global Market

Written by Customer Service on March 6, 2026. Posted in Public Companies.

Company Highlights Recent Financial and Operational Momentum Following Third Quarter and Nine-Month Fiscal 2026 Results AUSTIN, Texas., March 06, 2026 (GLOBE NEWSWIRE) — Virtuix Inc. (NASDAQ: VTIX), a leading developer of full-body virtual reality systems, celebrated the ringing of the Nasdaq Closing Bell at the Nasdaq MarketSite in Times Square, New York City on March 5, 2026. The ceremony recognized Virtuix’s listing on the Nasdaq Global Market under the ticker symbol “VTIX,” which began trading on January 27, 2026. Virtuix Founder, Chief Executive Officer, and Chairman Jan Goetgeluk participated in the ceremony alongside Nasdaq officials, members of the Virtuix Board of Directors and management team, employees, and guests. A replay of the Nasdaq Closing Bell ceremony is available here. “We were honored to ring the Nasdaq Closing...

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Written by Customer Service on March 6, 2026. Posted in Earnings Releases And Operating Results.

– 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival;On track for expanded pancreatic cancer cohort data readout in first half of 2026 – – On track to dose first patient in pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in patients with first-line metastatic pancreatic cancer in mid-2026 – – Dosing in Phase 2 trial of atebimetinib + Libtayo® in patients with first-line RAS-mutant non-small cell lung cancer expected to begin in second half of 2026 – – Ended 2025 with $217 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 – NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) — Immuneering...

GXO Appoints Mark Suchinski as Chief Financial Officer

Written by Customer Service on March 6, 2026. Posted in Public Companies.

Mark SuchinskiGXO Appoints Mark Suchinski as Chief Financial OfficerGREENWICH, Conn., March 06, 2026 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, today announced the appointment of Mark Suchinski as Chief Financial Officer, effective April 1, 2026. Suchinski is a seasoned financial leader with more than three decades in finance, operations and supply chain management, with significant experience in the aerospace and defense sector, a key growth vertical for GXO. He has a proven track record driving enterprise performance improvement in labor productivity, contracting, pricing and sourcing. GXO CEO Patrick Kelleher said, “Mark is an accomplished corporate finance leader with decades of operational and supply chain experience and deep expertise in aerospace...

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Written by Customer Service on March 6, 2026. Posted in Earnings Releases And Operating Results.

JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated in 2027 JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected to advance into first-in-human clinical trial in rheumatoid arthritis patients in the second quarter of 2026; interim data anticipated in 2027 Third development candidate, JADE301, nominated; Phase 1 clinical trial expected to commence in the first half of 2027 $336 million of cash, cash equivalents, and investments as of December 31st, 2025 expected to provide runway into the first half of 2028SAN FRANCISCO and VANCOUVER, British Columbia, March 06, 2026 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO),...

Day: March 6, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals